Insider Selling: Oric Pharmaceuticals (NASDAQ:ORIC) CFO Sells $159,720.00 in Stock

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Dominic Piscitelli sold 11,000 shares of the stock in a transaction that occurred on Monday, October 6th. The stock was sold at an average price of $14.52, for a total transaction of $159,720.00. Following the transaction, the chief financial officer owned 48,317 shares in the company, valued at approximately $701,562.84. The trade was a 18.54% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Oric Pharmaceuticals Stock Performance

Shares of NASDAQ ORIC opened at $13.68 on Friday. Oric Pharmaceuticals, Inc. has a 52 week low of $3.90 and a 52 week high of $14.93. The stock has a market capitalization of $1.33 billion, a P/E ratio of -7.24 and a beta of 1.68. The stock’s fifty day moving average is $10.74 and its 200 day moving average is $8.75.

Oric Pharmaceuticals (NASDAQ:ORIC) last released its earnings results on Tuesday, August 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.01). Equities research analysts forecast that Oric Pharmaceuticals, Inc. will post -2.17 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on ORIC shares. Zacks Research raised shares of Oric Pharmaceuticals to a “hold” rating in a research note on Tuesday, August 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research report on Wednesday. Wedbush reiterated an “outperform” rating and issued a $20.00 price target on shares of Oric Pharmaceuticals in a report on Monday, June 23rd. HC Wainwright cut their price target on Oric Pharmaceuticals from $22.00 to $19.00 and set a “buy” rating on the stock in a report on Thursday, August 14th. Finally, LADENBURG THALM/SH SH initiated coverage on Oric Pharmaceuticals in a report on Tuesday, July 8th. They issued a “buy” rating and a $15.00 target price on the stock. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $17.29.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. MPM Bioimpact LLC bought a new position in shares of Oric Pharmaceuticals during the 1st quarter worth approximately $7,809,000. JPMorgan Chase & Co. lifted its holdings in Oric Pharmaceuticals by 3,646.1% during the second quarter. JPMorgan Chase & Co. now owns 1,335,448 shares of the company’s stock worth $13,555,000 after acquiring an additional 1,299,799 shares during the period. Vivo Capital LLC lifted its holdings in Oric Pharmaceuticals by 50.3% during the second quarter. Vivo Capital LLC now owns 3,126,604 shares of the company’s stock worth $31,735,000 after acquiring an additional 1,046,154 shares during the period. Eventide Asset Management LLC bought a new stake in Oric Pharmaceuticals during the second quarter worth $9,657,000. Finally, Alkeon Capital Management LLC lifted its holdings in Oric Pharmaceuticals by 12.5% during the second quarter. Alkeon Capital Management LLC now owns 4,504,096 shares of the company’s stock worth $45,717,000 after acquiring an additional 500,000 shares during the period. 95.05% of the stock is owned by institutional investors.

About Oric Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.